Education
About Us
Working with TipRanks
Follow Us
Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
TNYA Stock Chart & Stats
$1.66
-$0.05(-3.69%)
At close: 4:00 PM EST
$1.66
-$0.05(-3.69%)
Day’s Range― - ―
52-Week Range$0.36 - $4.01
Previous CloseN/A
Volume1.07M
Average Volume (3M)4.19M
Market Cap
$270.54M
Enterprise Value$40.04M
Total Cash (Recent Filing)$71.67M
Total Debt (Recent Filing)$12.21M
Price to Earnings (P/E)―
Beta2.78
Next Earnings
Nov 05, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding162,976,100
10 Day Avg. Volume5,920,511
30 Day Avg. Volume4,191,660
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-19.21
Enterprise Value/Ebitda-0.43
Forecast
1Y Price Target
$10.14Price Target Upside510.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Data Insights And ExecutionUpcoming data readouts for gene therapy programs are expected to focus on tolerability and biopsy results, highlighting ongoing execution.
Gene Therapy AdvancementsTenaya is developing two AAV-based gene therapy approaches for the treatment of cardiomyopathies, which are expected to halt disease progression and improve symptoms after a single dose.
Protein Measurement InnovationsTenaya has developed a highly sensitive and reproducible assay to quantify TN-201 or TN-401 protein products from patient cardiac biopsies.
Bears Say
Cash Overhang ConcernsThe cash overhang will likely impact, despite the risk/reward into these updates being favorable.
Complexity In Efficacy AssessmentIt remains complicated to discern whether the gene therapy is working due to varying levels of endogenous protein in patients.
Financial ConstraintsTenaya Therapeutics has an annualized cash burn of $80 million with only approximately 0.9 years of cash left.
Tenaya Therapeutics News
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $0.36 and its highest was $4.01 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Tenaya Therapeutics’s market cap is $270.54M.
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 7 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.189 by $0.049.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -0.15.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 162,976,100 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.189. Following the earnings report the stock price went down -1.493%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Currently, no hedge funds are holding shares in TNYA
Tenaya Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.14 (510.84% Upside)
$10.14 (510.84% Upside)
Hedge Fund Trend
Decreased
By 5.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $26.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.81%
12-Months-Change
Fundamentals
Return on Equity
-85.21%
Trailing 12-Months
Asset Growth
-25.15%
Trailing 12-Months
Company Description
Tenaya Therapeutics
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
TNYA Stock 12 Month Forecast
Average Price Target
$10.14
▲(510.84% Upside)
Technical Analysis
Galectin Therapeutics
―
Abeona Therapeutics
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Candel Therapeutics
―
Ownership Overview
72.79% Insiders
3.59% Mutual Funds
0.01% Other Institutional Investors
21.18% Public Companies and Individual Investors